CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis

The HER2-specific monoclonal antibody (mAb), trastuzumab, has been the mainstay of therapy for HER2(+) breast cancer (BC) for approximately 20 years. However, its therapeutic mechanism of action (MOA) remains unclear, with antitumor responses to trastuzumab remaining heterogeneous and metastatic HER...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JCI Insight
Main Authors: Tsao, Li-Chung, Crosby, Erika J., Trotter, Timothy N., Agarwal, Pankaj, Hwang, Bin-Jin, Acharya, Chaitanya, Shuptrine, Casey W., Wang, Tao, Wei, Junping, Yang, Xiao, Lei, Gangjun, Liu, Cong-Xiao, Rabiola, Christopher A., Chodosh, Lewis A., Muller, William J., Lyerly, Herbert Kim, Hartman, Zachary C.
Format: Artigo
Sprog:Inglês
Udgivet: American Society for Clinical Investigation 2019
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6975273/
https://ncbi.nlm.nih.gov/pubmed/31689243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.131882
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker